International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin Receptor Function, Nomenclature and Pharmacology

  title={International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin Receptor Function, Nomenclature and Pharmacology},
  author={Anthony L Gotter and Andrea L Webber and Paul J. Coleman and John J. Renger and Christopher J Winrow},
  journal={Pharmacological Reviews},
  pages={389 - 420}
Orexin signaling is essential for normal regulation of arousal and behavioral state control and represents an attractive target for therapeutics combating insomnia. [] Key Result Orexin receptor antagonists of varying specificity uncovered additional roles beyond sleep and feeding that include addiction, depression, anxiety, and potential influences on peripheral physiology. Combined genetic and pharmacological approaches indicate that orexin signaling may represent a confluence of sleep, feeding, and reward…

Figures and Tables from this paper

Discovery and development of orexin receptor antagonists as therapeutics for insomnia

Based on the publication of recent non‐clinical and clinical data, orexin receptor antagonists potentially represent a targeted, effective and well‐tolerated new class of medications for insomnia.

Orexin receptors: a journey through their discovery to the development of suvorexant, the new sleeping pill -

A review focuses on the orexinergic system, their physiological action and potential role as pharmacological targets, and the approval of suvorexant by United States food and drug administration in 2014.

Orexin Receptor Antagonists

It is proposed that REM sleep enhancement by DORAs may provide opportunities to treat specific neurological disorders and OX2R antagonists such as seltorexant may have broader applications as they appear to promote balanced sleep architecture in preclinical models and should, in theory, have a lower narcoleptic/cataplectic potential.

Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia.

From a structural perspective, this perspective will focus on the discovery and development of structurally diverse orexin antagonists suitable for preclinical pharmacology studies and human clinical trials.

The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia.

Among DORAs evaluated clinically, suvorexant has pharmacokinetic properties engineered for a plasma half-life appropriate for rapid sleep onset and maintenance at low to moderate doses, and the preservation of cognitive performance and the ability to arouse to salient stimuli after DORA administration suggest further advantages over historical therapies.

Orexin OX2 Receptor Antagonists as Sleep Aids.

The evidence that an OX2R antagonist should be at least equivalent, or perhaps superior, to a DORA for the treatment of insomnia is reviewed, with a view to finding the ideal orexin agent to achieve a balanced increase in REM and non-rapid eye movement (NREM) sleep.

The Orexin receptors: Structural and anti-tumoral properties

The identification of OX1R expression in digestive cancers encompassing colon, pancreas and liver cancers and its ability to trigger mitochondrial apoptosis in tumoral cells, indicate a new putative therapeutical action of orexins and paradoxically OXR antagonists.

Therapeutics development for addiction: Orexin-1 receptor antagonists

Orexin/Hypocretin Based Pharmacotherapies for the Treatment of Addiction: DORA or SORA?

The question of whether to use a DORA or single orexin receptor antagonist (SORA) for the treatment of addiction is a key question that will need to be answered in order to maximize the clinical utility of orexIn receptor antagonists.



Discovery process and pharmacological characterization of a novel dual orexin 1 and orexin 2 receptor antagonist useful for treatment of sleep disorders.

Orexins and their receptors: structural aspects and role in peripheral tissues

This new multifaceted aspect of orexin biology is reviewed here in descriptions of the pro-form, maturation and structure of o Rexins, the structure, signal transduction and pharmacology of oX1R and OX2R receptors, and the expression of oxin receptors as well as their biological role in the hypothalamus-pituitary-adrenal axis, gastrointestinal tract, endocrine pancreas and other peripheral tissues.

Orexins: from neuropeptides to energy homeostasis and sleep/wake regulation

Although narcoleptic patients rarely have genetic defects in the orexin system, they lack these neuropeptides in the brain and cerebrospinal fluid, indicating that human Narcolepsy is an orexIn deficiency syndrome in the majority of cases.

Promotion of Sleep by Suvorexant—A Novel Dual Orexin Receptor Antagonist

Dosed orally Suvorexant significantly and dose-dependently reduced locomotor activity and promoted sleep in rats, dogs, and rhesus monkeys, highlighting a unique opportunity to develop dual orexin antagonists as a novel therapy for insomnia.

Orexin receptors: pharmacology and therapeutic opportunities.

As the orexin system mainly promotes arousal, these new compounds will likely improve insomnia without incurring many of the side effects encountered with current medications.

Narcolepsy and Orexins: An Example of Progress in Sleep Research

Through an evaluation of the scientific literature, an updated picture of narcolepsy and orexins is traced in order to provide insight into the means by which neurobiological knowledge is constructed.

Pharmacological characterization of MK-6096 – A dual orexin receptor antagonist for insomnia

Orexins and gastrointestinal functions.

The aim of the proposed review is to summarize both centrally- and peripherally-mediated actions of orexins on gastrointestinal functions and to discuss the related physiological role on the basis of the most recent findings.

Orexin neuronal circuitry: Role in the regulation of sleep and wakefulness

Functional Magnetic Resonance Imaging Reveals Different Neural Substrates for the Effects of Orexin-1 and Orexin-2 Receptor Antagonists

Functional magnetic resonance imaging in the rat is used to map the modulatory effect of selective OXR blockade on the functional response produced by D-amphetamine, a psychostimulant and arousing drug that stimulates orexigenic activity.